Management of Calcineurin Inhibitors-Related Chronic Kidney Disease in Cardiac Transplantation

Brieke Andreas,D. Lowes Brian,Andreas Brieke Brian D. Lowes

DOI: https://doi.org/10.4172/2329-9517.1000117

2013-01-01

Abstract:Background: The use of calcineurin inhibitors revolutionized transplantation by prolonging patients’ survival. However, their utility is limited by the development of significant chronic kidney disease.

What problem does this paper attempt to address?

The effect of calcineurin inhibitors on endothelial function in renal transplant recipients

Huseyin Oflaz,Aydin Turkmen,Rumeyza Kazancioglu,Seyit M Kayacan,Banu Bunyak,Hakan Genchallac,Bulent Erol,Fehmi Mercanoglu,Sabahattin Umman,Mehmet S Sever

DOI: https://doi.org/10.1034/j.1399-0012.2003.00030.x

Abstract:Endothelial dysfunction is of vital importance, as it may cause ischemia and dysfunction in various organs. Despite, this problem has been well documented in patients with end-stage renal disease (ESRD), there is not enough data considering this issue following renal transplantation. One of the potential causes of endothelial dysfunction in renal transplant recipients may be administration of calcineurin inhibitors. The aim of this study is to evaluate the effects of two different calcineurin inhibitors [cyclosporin A (CsA) and tacrolimus (FK506)] on endothelial function in renal transplant patients. Forty-four renal transplant recipients [22 on FK506 (group I) and 22 on CsA (group II)] were studied. Endothelial functions of the brachial artery were evaluated by using high resolution vascular ultrasound. Endothelium-dependent and -independent vasodilations were assessed by establishing reactive hyperemia and using sublingual nitroglycerine (NTG), respectively. Results are presented as percentage change from baseline values. Significant endothelial dysfunction was noted in renal transplant patients treated with CsA. While endothelium-dependent vasodilation was 12.1 +/- 5.1% in group I and it was 6.5 +/- 3.7% in group II (p < 0.001). The increase in brachial artery diameter after sublingual NTG was 20.1 +/- 6.3 and 12.7 +/- 5.6% in groups I and II, respectively. This indicates that the endothelium-dependent and -independent vasodilation of the patients on FK506 is better preserved than the patients on CsA therapy. Besides, blood flow volume (BFV) increase was 51.2 +/- 39.4 and 43.9 +/- 24.3%, in groups I and II, respectively, in reactive hyperemia period (p > 0.05). Post-transplant course of renal transplant recipients is complicated by endothelial dysfunction. This problem is more prominent in patients on CsA therapy, which can predispose these patients to more frequent cardiac complications.
Calcineurin-Inhibitor Minimization In Liver Transplant Patients With Calcineurin-Inhibitor-Related Renal Dysfunction: A Meta-Analysis

Yuan Kong,Dongping Wang,Yushu Shang,Wenhua Liang,Xiaoting Ling,Zhiyong Guo,Xiaoshun He

DOI: https://doi.org/10.1371/journal.pone.0024387

IF: 3.7

2011-01-01

PLoS ONE

Abstract:Background: Introduction of calcineurin-inhibitor (CNI) has made transplantation a miracle in the past century. However, the side effects of long-term use of CNI turn out to be one of the major challenges in the current century. Among these, renal dysfunction attracts more and more attention. Herein, we undertook a meta-analysis to evaluate the efficacy and safety of calcineurin-inhibitor (CNI) minimization protocols in liver transplant recipients with CNI-related renal dysfunction.Methods: We included randomized trials with no year and language restriction. All data were analyzed using random effect model by Review Manager 5.0. The primary endpoints were glomerular filtration rate (GFR), serum creatinine level (sCr) and creatinine clearance rate (CrCl), and the secondary endpoints were acute rejection episodes, incidence of infection and patient survival at the end of follow-up.Results: GFR was significantly improved in CNI minimization group than in routine CNI regimen group (Z = 5.45, P<0.00001; I-2 = 0%). Likely, sCr level was significantly lower in the CNI minimization group (Z = 2.84, P = 0.005; I-2 = 39%). However, CrCl was not significantly higher in the CNI minimization group (Z = 1.59, P = 0.11; I-2 = 0%). Both acute rejection episodes and patient survival were comparable between two groups (rejection: Z = 0.01, P = 0.99; I-2 = 0%; survival: Z = 0.28, P = 0.78; I-2 = 0%, respectively). However, current CNI minimization protocols may be related to a higher incidence of infections (Z = 3.06, P = 0.002; I-2 = 0%).Conclusion: CNI minimization can preserve or even improve renal function in liver transplant patients with renal impairment, while sharing similar short term acute rejection rate and patient survival with routine CNI regimen.
Treatment with calcimimetics in kidney transplantation

Enrique Morales,Eduardo Gutierrez,Amado Andres

DOI: https://doi.org/10.1016/j.trre.2010.01.001

Abstract:Graft and patient survival in renal transplantation has increased with better immune suppression treatment, leading to the appearance of new complications such as posttransplant bone disease. After renal transplantation and the recovery of renal function, mineral metabolism disorders secondary to renal failure could be expected to normalize. However, both immediately after transplantation and later, and even with good renal graft function, we see bone disorders associated to renal osteodystrophy, a high incidence of osteopenia, persistent hyperparathyroidism, hypercalcemia, hypophosphoremia, and less commonly, aseptic bone necrosis. The causes potentially responsible for these disorders have basically been identified as different degrees of renal insufficiency in the graft, persistent posttransplant secondary hyperparathyroidism, and negative impact of immunosuppression treatment, particularly corticosteroids. The most important factor in the evolution of metabolic and bone disorders after renal transplantation, however, is pretransplant bone status. Special attention should be paid to other osteoarticular complications such as loss of bone mass and fractures, leading to significant morbidity. In the therapeutic approach to these patients, as well as encouraging physical exercise and advice about diet or other habits, the use of drugs such as calcium and vitamin D supplements, bisphosphonates, and more recently, calcimimetics have made significant improvements in the prevention and treatment of bone-mineral metabolism. It has been shown that calcimimetic agents can control the parathyroid hormone, reduce episodes of hypercalcemia, and improve hypophosphatemia. Their properties have to be assessed in broader studies to establish the basis for their widespread use among renal transplant recipients.
Progress in the Application of Immunosuppressants to Renal Transplant

陈江华

DOI: https://doi.org/10.3969/j.issn.1672-6170.2008.04.004

2008-01-01

Abstract:Short-term renal allograft survival is significantly improved with the application of immunosuppressant.Renal toxicity of immunosuppressants(such as calcineurin) is the important factor affecting long-term renal allograft survival.In recent years,long-term renal allograft survival becomes possible with the emergence of new immunosuppressants as rapamycin,FTY720,as well as new immunosuppressive regimens such as low dose,steroid-free,or calcineurin-free immunosuppressives.The paper reviews the new progress of immunosuppressants in renal transplant.
Calcineurin inhibitors and the renin–angiotensin–aldosterone system

Mesut Berber,David Penton

DOI: https://doi.org/10.1111/apha.14248

IF: 7.523

2024-10-27

Acta Physiologica

Abstract:Calcineurin inhibitors (CnIs) are effective immunosuppressants with decades of accumulated experience in treating immune disorders and, most notably, solid organ transplantation. While CnIs have significantly increased graft survival and transformed the patient standard of care, their use has been overshadowed by a number of undesired side effects. For instance, CnI‐associated nephrotoxicity has been reported since early studies and remains a major therapeutic concern. The occurrence of several ion imbalances alongside hypertension was also noted early on, indicating the involvement of the renin–angiotensin–aldosterone system (RAAS) in CnI‐mediated toxicity. However, the literature in this field is crowded with conflicting reports from clinical trials as well as studies using animal and invitro models. With this review, we aim to provide a structured and updated overview of the physiological and pathophysiological evidence supporting the involvement of the classical RAAS in CnI‐associated toxicity.

physiology
Calcineurin inhibition, cardiovascular consequences, vascular resistance, and potential responses

Friedrich C. Luft

DOI: https://doi.org/10.1111/apha.14084

IF: 7.523

2024-01-13

Acta Physiologica

Abstract:Aim To place the consequences of calcineurin inhibition in a cardiovascular context. Methods Literature review coupled with personal encounters. Results Calcineurin is a calcium‐binding and calmodulin‐binding protein that is conserved across evolution from yeast to mammals. The enzyme functions as a calcium‐dependent, calmodulin‐stimulated protein phosphatase. Its role in regulating physiology has largely been elucidated by observing calcineurin inhibition. Calcineurin inhibition transformed organ transplantation from an experiment into a therapy and made much of general immunotherapy possible. The function of this phosphatase and how its inhibition leads to toxicity concern us to this date. Initial research from patients and animal models implicated a panoply of factors contributing to hypertension and vasculopathy. Subsequently, the role of calcineurin in regulating the effective fluid volume, sodium reabsorption, and potassium and hydrogen ion excretion was elucidated by investigating calcineurin inhibition. Understanding the regulatory effects of calcineurin on endothelial and vascular smooth muscle cell function has also made substantial progress. However, precisely how the increase in systemic vascular resistance arises requires further mechanistic research. Conclusion Calcineurin inhibition continues to save lives; however, options to counteract the negative effects of calcineurin inhibition should be vigorously pursued.

physiology
Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

Rending Wang,Ying Xu,Jianyong Wu,Yimin Wang,Qiang He,Jianghua Chen

DOI: https://doi.org/10.2169/internalmedicine.52.8457

2013-01-01

Internal Medicine

Abstract:OBJECTIVE:It remains debated whether reduced doses of chronic calcineurin inhibitors benefit graft survival.METHODS:This retrospective study analyzed 60 first cadaveric renal transplant recipients who received cyclosporine (CSA), mycophenolate mofetil (MMF) and prednisone (CMP group) and 71 recipients who received reduced-dose CSA with prednisone and MMF (RCMP group). All recipients were followed for at least 96 months. The Modification of Diet in Renal Disease (MDRD) glomerular filtration rate (GFR) calculated at different time points, graft survival, the incidence of chronic allograft nephropathy (CAN) and the acute rejection rate within six months were analyzed and compared between the two groups.RESULTS:The incidence of acute rejection within six months post-transplant was 15.5% (11/71) in the RCMP group and 13.3% (8/60) in the CMP group. This difference was not significant (p=0.727). The MDRD-calculated GFR in the CMP group reached a peak at 24 months post-transplant (66.6 ± 20.2 mL/min/1.73 m(2)) then decreased gradually. In contrast, in the RCMP group, the GFR reached a peak at 36 months post-transplant (76.9 ± 19.6 mL/min/1.73 m(2)). The GFR from month 36 to month 96 was significantly higher in the RCMP group than in the CMP group. The Kaplan-Meier calculated death-censored graft survival in the RCMP group was significantly higher than that observed in the CMP group, with an estimated cumulative proportion surviving at 96 months of 95.5% in the RCMP group and 83.5% in the CMP group. The incidence of CAN within 96 months was 5.6% (4/71) in the RCMP group vs. 16.7% (10/60) in the CMP group (p=0.042).CONCLUSION:An RCMP regimen can significantly improve the long-term GFR level and benefit graft survival.
Prophylaxis of Chronic Kidney Disease after Liver Transplantation - Experience from West China

Zhen-Yong Shao,Lu-Nan Yan,Wen-Tao Wang,Bo Li,Tian-Fu Wen,Jia-Yin Yang,Ming-Qing Xu,Ji-Chun Zhao,Yong-Gang Wei

DOI: https://doi.org/10.3748/wjg.v18.i9.991

IF: 5.374

2012-01-01

World Journal of Gastroenterology

Abstract:AIM:To evaluate the prophylaxis of chronic kidney disease (CKD) after liver transplantation (LT) with low-dose calcineurin inhibitor (CNI) and mycophenolate mofetil (MMF). METHODS:From March 1999 to December 2009, a total of 572 patients (478 males and 94 females) underwent LT enrolled in the study.Initial immunosuppression was by triple-drug regimens that included a CNI, MMF, and prednisone.The initial dose of CNI was 0.05-0.10mg/kg per day for tacrolimus (TAC) and 5-10 mg/kg per d for cyclosporine A (CSA) respectively, and was gradually reduced based on a stable graft function.The serum trough level of CNI was 6-8 ng/mL for TAC and 120-150 ng/mL for CSA 3-mo post-operation, 4-6 ng/mL for TAC and 80-120 ng/mL for CSA 1-year after transplantation was expected with stable liver function.MMF was personalized between 1.0-1.5 g/d.Glomerular filtration rate (GFR) was estimated by an abbreviated Modification of Diet in Renal Disease formula.Risk factors of CKD were examined by univariate and multivariate logistic regression. RESULTS:With a definition of GFR < 60 mL/min per 1.73 m 2 , the incidence of CKD was 17.3% 5-year after LT.There were 68.3% (293 of 429 cases) patients managed to control their TAC trough concentrations within 8 ng/mL and 58.0%(83 of 143 cases) patients' CSA trough concentrations within 150 ng/mL.Of the 450 recipients followed-up over 1 year, 55.5% (183 of 330 cases) of which were treated with TAC had a trough concentration ≤ 6 ng/mL while 65.8% (79 of 120 cases) of which were treated with CSA had a concentration ≤ 120 ng/mL.The incidence of CKD in the groups of lower CNI trough concentrations was significantly lower than the groups with CNI concentrations above the ideal range.Patients with CKD had much higher CNI trough concentrations than that of patients without CKD.MMF was adopted in 359 patients (62.8%).Patients administrated with MMF had a relatively low CNI trough concentrations but with no significant difference.The graft function remained stable during follow-up.No difference was found between different groups of CNI trough concentrations.Pre-LT renal dysfunction, ages, acute kidney injury, high blood trough concentrations of CNI in 3 mo (TAC > 8 ng/mL, CSA > 150 ng/mL) and hypertension after operation were associated with CKD progression, while male gender and adoption of MMF were protection factors. CONCLUSION:Low dose of CNI combined with MMF managed to prevent CKD after LT with stable graft function.
Development of calciphylaxis in kidney transplant recipients with a functioning graft

Elena Guillén-Olmos,Jose Vicente Torregrosa,Adriana Garcia-Herrera,Sergi Ganau,Fritz Diekmann,David Cucchiari

DOI: https://doi.org/10.1093/ckj/sfab205

2021-10-26

Abstract:Background: Calciphylaxis is not uniquely observed in uraemic patients, as some cases have also been reported in patients with normal renal function or moderate chronic kidney disease (CKD), in association with severe vasculopathy or systemic inflammation. A particular subset worthy of studying is represented by those patients who develop calciphylaxis after kidney transplantation (KT). Methods: Analysis of the local series of calciphylaxis after KT (n = 14) along with all the other cases reported in the literature from 1969 to 2019 (n = 31), for a total population of 45 patients, is presented. Demographic data, CKD history, risk factors, immunosuppression, clinical presentation and management have been analysed both as a whole and according to the time period (before or after the year 2000). Results: Calciphylaxis developed during the first year after KT in 43.2% of patients and median (interquartile range) creatinine at diagnosis was 2.4 (1.25-4.64) mg/dL. The most frequent presentation included distal purpura or ulcers in one-third of cases and 39.1% of patients were receiving vitamin K antagonists. PTH values were above 500 pg/mL and below 100 pg/mL in 50.0% and 25.0% of cases, respectively. Whole population mortality was 55.6%. As expected, clinical presentation, immunosuppression and management varied depending on the time period. Patients diagnosed after 2000 were older, with longer dialysis vintage, and treatment was usually multimodal; on the contrary, in patients diagnosed before 2000, parathyroidectomy was the treatment of choice in 61.9% of cases. Conclusions: Calciphylaxis can still occur after KT, in many cases during the first year and in patients with a good renal function. Risk factors and management varied according to the time period studied.
Systematic Review of Calcineurin Inhibitors and Incidence of Skin Malignancies after Kidney Transplantation in Adult Patients: A Study of 309,551 Cases

Aleksandra Kulbat,Karolina Richter,Tomasz Stefura,Marta Kołodziej-Rzepa,Michał Kisielewski,Tomasz Wojewoda,Wojciech M Wysocki

DOI: https://doi.org/10.3390/curroncol30060430

2023-06-13

Abstract:The purpose of this systematic review and meta-analysis was to compare the risk of non-melanoma skin cancer (NMSC) and melanoma development in renal transplant recipients who receive calcineurin inhibitors to that of patients treated with other immunosuppressive agents, and investigate the possible association between the type of maintenance immunosuppression and the incidence of NSMC and melanoma in this group of patients. The authors searched databases such as PubMed, Scopus, and Web of Science for articles that would help establish the influence of calcineurin inhibitors on skin cancer development. The inclusion criteria for the study consisted of randomized clinical trials, cohort studies, and case-control studies that compared patients who received kidney transplants and were treated with a calcineurin inhibitor (CNI), such as cyclosporine A (CsA) or tacrolimus (Tac), to those who received alternative immunosuppressants and did not receive a CNI. Seven articles were analyzed overall. The results revealed a correlation between CNI treatment in renal transplant recipients and increased total skin cancer risk (OR 1.28; 95% CI: 0.10-16.28; p < 0.01), melanoma risk (OR 1.09; 95% CI: 0.25-4.74; p < 0.01), and NMSC risk (OR 1.16; 95% CI: 0.41-3.26; p < 0.01). In conclusion, the calcineurin inhibitors used after kidney transplantation are associated with a higher risk of skin cancer-both non-melanoma and melanoma-when compared with other immunosuppressive therapies. This finding suggests that careful monitoring for skin lesions in post-transplant patients must be conducted. However, the decision on the kind of immunotherapy used should always be considered on an individual basis for each renal transplant recipient.
Calciphylaxis after kidney transplantation: a rare but life-threatening disorder

Manuel Alfredo Podestà,Paola Ciceri,Andrea Galassi,Mario Cozzolino

DOI: https://doi.org/10.1093/ckj/sfab247

2021-12-15

Abstract:Calciphylaxis is a rare disorder characterized by vascular calcification and thrombosis of the subcutaneous microcirculation, leading to painful necrotic skin lesions and bearing a dreadfully high mortality rate. This syndrome is frequently also termed uraemic calcific arteriolopathy, since most cases are observed in patients with kidney failure. However, it is increasingly clear that calciphylaxis may also affect patients with normal or only slightly impaired renal function, including kidney transplant recipients. A precise definition of the characteristics and risk factors of calciphylaxis developing after kidney transplantation has been hindered by the extreme rarity of this condition, which also hampered the development of effective therapeutic strategies. In the present issue of CKJ, Guillén and colleagues report the largest case series of calciphylaxis in kidney transplant recipients to date, outlining several features that are apparently specific to this population. In this editorial, we briefly present the epidemiology and pathogenesis of calciphylaxis in different patient populations and discuss recent findings for its therapeutic management.
Long-term clinicopathological impact of calcineurin inhibitor cessation without specific cytoreductive induction in kidney transplantation

Tatsu Tanabe,Ken Morita,Hiromi Fujita,Kanako Hatanaka,Yayoi Ogawa,Takayuki Hirose,Hajime Sasaki,Daiki Iwami,Kiyohiko Hotta,Katsuya Nonomura

DOI: https://doi.org/10.1111/ctr.12274

Abstract:Calcineurin inhibitors (CNIs) have considerably improved renal allograft survival. However, their chronic use has various adverse effects, including hypertension, hyperlipidemia, and nephrotoxicity. We conducted a retrospective study of kidney transplant recipients using a CNI withdrawal protocol. Eleven of 13 patients who had stable graft function on triple-drug therapy including a cyclosporine (CsA) were enrolled in this study. The dose of CsA was reduced by 20% every two wks until complete withdrawal. The mean period between the baseline and last biopsies was 97 (range: 21-123) months. No patient had an acute rejection episode during follow-up. Progression of interstitial fibrosis and tubular atrophy was seen in five and six cases, respectively. Arteriolar hyalinosis improved in three cases, but worsened in four. No patient lost his graft during the study. The mean serum creatinine level was 1.30 ± 0.26 mg/dL at baseline and stable for 10 yr after elimination (1.26 ± 0.11 mg/dL). At the end of the study, four of the eleven patients had reduced their antihypertensive drugs, and one patient had stopped hyperlipidemia treatment. CNI withdrawal can be implemented safely in stable renal transplant recipients and might lead to improved patient outcomes. Additional specific evidence of CNI nephrotoxicity should be elucidated.
Chronic Cyclosporine Nephrotoxicity: New Insights and Preventive Strategies

Can Li,Sun Woo Lim,Bo Sun,Chul Woo Yang

DOI: https://doi.org/10.3349/ymj.2004.45.6.1004

2004-01-01

Abstract:Cyclosporine (CsA) has improved patient and graft survival rates following solid-organ transplantation and has been increasingly applied with significant clinical benefits in the management of autoimmune diseases. However, the clinical use of CsA is often limited by acute and chronic nephrotoxicity, which remains a major problem. Acute nephrotoxicity depends on the dosage of CsA and seems to be caused by a reduction in renal blood flow related to afferent arteriolar vasoconstriction. However, the mechanisms underlying chronic CsA nephrotoxicity are not fully understood. Activation of the intrarenal renin-angiotensin system, increased release of endothelin-1, dysregulation of nitric oxide (NO) and NO synthase, upregulation of transforming growth factor-beta1, inappropriate apoptosis, stimulation of inflammatory mediators, and enhanced immunogenecity have all been implicated in the pathogenesis of chronic CsA nephrotoxicity. Reducing the CsA dose or withdrawing it and using combined nephroprotective drugs (mycophenolate mofetil, losartan, and pravastatin) may ameliorate chronic CsA-induced renal injury. This review discusses new insights and preventive strategies for this clinical dilemma.
Immunosuppression in Kidney Transplant Recipients: An Update for the General Nephrologist

Bassam G Abu Jawdeh,Hay Me Me

DOI: https://doi.org/10.1053/j.akdh.2024.05.001

Abstract:Over the last 7 decades, kidney transplantation has evolved from an experiment between identical twins to becoming the gold standard treatment for end-stage kidney disease. To date, mycophenolate and calcineurin inhibitors, with or without prednisone, continue to constitute the backbone of modern maintenance immunosuppression. Despite major strides in improving acute rejection, long-term outcomes remain suboptimal with current regimens. Alternatives to calcineurin inhibitors such as belatacept and mammalian targets of rapamycin inhibitors exist; however, their wider-scale adoption remains relatively delayed due to concerns about increased rejection rates. In addition to continuing the investigation of steroid and calcineurin inhibitor sparing protocols, it is time to identify measurable surrogates for meaningful long-term graft survival. iBOX, a dynamic risk-prediction tool that predicts long-term death-censored graft failure could be a potential surrogate end point for future immunosuppression clinical trials. In this review, we summarize the landmark studies supporting current immunosuppression protocols and briefly discuss challenges and future directions.
Calcineurin inhibitors' impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain

Rita Nogueiras-Álvarez,Víctor Manuel Mora-Cuesta,José Manuel Cifrián-Martínez,María Ángeles de Cos-Cossío,María Del Mar García-Sáiz

DOI: https://doi.org/10.1038/s41598-022-25445-2

2022-12-08

Abstract:Patients undergoing lung transplantation (LTx) need administration of immunosuppressive therapy following the procedure to prevent graft rejection. However, these drugs are not exempt from potential risks. The development of cardiovascular risk factors and impaired renal function in the post-transplantation period are conditions that may be favoured by the use of calcineurin inhibitor (CNI) drugs which could have repercussions on the quality of life and the post-transplantation evolution. To evaluate the cardiovascular and renal toxicity following the administration of CNI as maintenance immunosuppression in lung transplant recipients (LTRs) we reviewed a total number of 165 patients undergoing LTx between 01/01/2015 and 08/12/2018. They were divided into two groups according to the CNI drug administrated: cyclosporine (CsA-group) with 11 patients or tacrolimus (Tac-group), with 154 patients. We evaluated the de novo occurrence of arterial hypertension (HTN), diabetes mellitus (DM), hyperlipidemia and impaired renal function after initiation of CNI administration. In addition to that, the time until each of these events was assessed. A higher rate for developing HTN (p < 0.001) and impaired renal function (p = 0.047) was observed within the CsA-group. The new onset of hyperlipidemia was similar between both CNI groups and de novo appearance of DM was only documented in those LTRs receiving tacrolimus. In this LTRs retrospective study, it was observed that having ≥ 4 tacrolimus trough levels above the upper limit of the proposed interval for each specific post-LTx period was associated with an increased risk for developing renal impairment. No other statistically significant association was found between supratherapeutic CNIs blood levels and the evaluated toxicities.
Calcineurin Inhibitor - A Necessary Evil: Pharmacogenetical Approach to a Promising Future

Lexi Zhang,Chenli Gu,Shang Huang,Ruiming Rong,Tongyu Zhu

DOI: https://doi.org/10.36876/smju.1008

2015-01-01

SM Journal of Urology

Abstract:The backbone of modern immunosuppressant regimens after kidney transplantation is Calcineurin Channel Inhibitor (CNI) drugs including tacrolimus and cyclosporine A. Its mechanism is binding to immunophilins, forming complexes, binding to calcineurin, and leading to inhibition of T cell activation.Since CNI drugs are eliminated by cytochrome P450 system, especially the CYP3A subfamily, exploring their interaction exhibits great importance.It is known that CYP3A4 and CYP3A5 are involved in tacrolimus metabolism while CYP3A5 alone plays a major role in cyclosporine A metabolism.The polymorphism of CYP3A4 and CYP3A5 genes results in different CNI drugs dose requirements in transplant recipients.Pharmacogenetic approaches to figure out donors' and recipients' CYP3A4 and CYP3A5 genotypes may give us better understanding of pharmacodynamics of CNI drugs.Additionally, monitoring CNI blood concentration can reflect its pharmacokinetics.Combination of pharmacodynamics and pharmacokinetics may be used as a guide in clinical practice to administer CNI drugs in optimal dose, to avoid acute rejection or adverse effects of CNI drugs such as nephrotoxicity.
Calcineurin inhibitors and nephrotoxicity in children

Fei Liu,Jian-Hua Mao

DOI: https://doi.org/10.1007/s12519-018-0125-y

2018-01-01

World Journal of Pediatrics

Abstract:Background Calcineurin inhibitors (CNIs) are commonly given to transplant recipients of kidneys and other solid organs and to patients with immune disorders, such as steroid-resistant nephrotic syndrome, steroid-dependent nephrotic syndrome, and frequent relapse nephrotic syndrome. Although CNIs remain the most effective available immunosuppressant agent, there is clinical concern regarding possible long-term nephrotoxicity. This concern is especially significant in children who have a longer life expectancy and greater growth rate. Data sources In this review, we analyzed the literatures to identify original articles that examined use of CNIs in children who received organ transplantation and nephropathy to assess the available evidence of their nephrotoxicity. PubMed, Elsevier, and Tompson ISI Web of Knowledge were searched for identifying relevant papers. Results Clinical research supports the presence of CNI-related nephrotoxicity. However, some researchers have questioned the prevalence and seriousness of chronic CNIs nephrotoxicity, especially because the pathological lesions typically associated with long-term CNI use are nonspecific. Many researchers have focused on early markers of CNI nephrotoxicity, and the methods that may help prevent and manage nephrotoxicity. Conclusions Future research should focus on investigating early markers of CNI nephrotoxicity and strategies for improved immunosuppressant therapy, and developing alternative treatments. CNI-mediated nephrotoxicity should always be taken seriously in clinic.
Bridging the Gap Between CKD Management Paradigms in Transplant and Nontransplant Settings: Published Evidence, Challenges, and Perspectives

Inès Dufour,Elliott Van Regemorter,Nada Kanaan,Antoine Buemi,Tom Darius,Michel Mourad,Eric Goffin,Michel Jadoul,Arnaud Devresse,Valentine Gillion

DOI: https://doi.org/10.1097/TP.0000000000005186

2024-08-29

Transplantation

Abstract:Kidney transplantation (KT) is the best treatment for patients with kidney failure, associated with improved survival and quality of life compared with maintenance dialysis. However, despite constant improvements in the assessment and management of the alloimmune response, KT patients frequently demonstrate a reduced estimated glomerular filtration rate. Therefore, the usual complications of chronic kidney disease (CKD), such as anemia, hypertension, metabolic acidosis, hyperkalemia, or persistent secondary hyperparathyroidism, are highly prevalent after KT. However, their underlying mechanisms are different in the transplant setting (compared with the nontransplanted CKD population), and management recommendations are based on relatively poor-quality data. In recent years, new therapies have emerged, significantly improving kidney and cardiovascular outcomes of non-KT patients with CKD. Whether those new drugs could improve the outcomes of KT patients has largely been under investigated so far. In this review, we will address the challenges of the management of a KT patient with a reduced estimated glomerular filtration rate, cover the published evidence, and highlight the critical knowledge gaps.
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation

Henrik Ekberg,Hélio Tedesco‐Silva,A. Demirbaş,S̆ Vı́tko,Björn Nashan,Alp Gürkan,Raimund Margreiter,Christian Hugo,Josep M. Grinyó,Ulrich Frei,Yves Vanrenterghem,Pierre Daloze,Philip F. Halloran

DOI: https://doi.org/10.1056/nejmoa067411

2007-01-01

Abstract:Immunosuppressive regimens with the fewest possible toxic effects are desirable for transplant recipients. This study evaluated the efficacy and relative toxic effects of four immunosuppressive regimens.We randomly assigned 1645 renal-transplant recipients to receive standard-dose cyclosporine, mycophenolate mofetil, and corticosteroids, or daclizumab induction, mycophenolate mofetil, and corticosteroids in combination with low-dose cyclosporine, low-dose tacrolimus, or low-dose sirolimus. The primary end point was the estimated glomerular filtration rate (GFR), as calculated by the Cockcroft-Gault formula, 12 months after transplantation. Secondary end points included acute rejection and allograft survival.The mean calculated GFR was higher in patients receiving low-dose tacrolimus (65.4 ml per minute) than in the other three groups (range, 56.7 to 59.4 ml per minute). The rate of biopsy-proven acute rejection was lower in patients receiving low-dose tacrolimus (12.3%) than in those receiving standard-dose cyclosporine (25.8%), low-dose cyclosporine (24.0%), or low-dose sirolimus (37.2%). Allograft survival differed significantly among the four groups (P=0.02) and was highest in the low-dose tacrolimus group (94.2%), followed by the low-dose cyclosporine group (93.1%), the standard-dose cyclosporine group (89.3%), and the low-dose sirolimus group (89.3%). Serious adverse events were more common in the low-dose sirolimus group than in the other groups (53.2% vs. a range of 43.4 to 44.3%), although a similar proportion of patients in each group had at least one adverse event during treatment (86.3 to 90.5%).A regimen of daclizumab, mycophenolate mofetil, and corticosteroids in combination with low-dose tacrolimus may be advantageous for renal function, allograft survival, and acute rejection rates, as compared with regimens containing daclizumab induction plus either low-dose cyclosporine or low-dose sirolimus or with standard-dose cyclosporine without induction. (ClinicalTrials.gov number, NCT00231764 [ClinicalTrials.gov].).
Management of Long-Term complications from immunosuppression

Mark W Russo,William Wheless,Dionisios Vrochides

DOI: https://doi.org/10.1097/lvt.0000000000000341

2024-02-06

Liver Transplantation

Abstract:This review discusses long term complications from immunosuppressants after liver transplantation and the management of these complications. Common complications of calcineurin inhibitors include nephrotoxicity and metabolic diseases. Nephrotoxicity can be managed by targeting a lower drug level and/or adding an immunosuppressant of a different class. Metabolic disorders can be managed by treating the underlying condition and targeting a lower drug level. Gastrointestinal side effects and myelosuppression are common complications of antimetabolites that are initially managed with dose reduction or discontinuation if adverse events persist. Mammalian target of rapamycin inhibitors are associated with myelosuppression, proteinuria, impaired wound healing, and stomatitis which may require dose reduction or discontinuation. Induction agents and agents used for steroid refractory rejection or antibody mediated rejection are reviewed. Other rare complications of immunosuppressants are discussed as well.

gastroenterology & hepatology,surgery,transplantation

Management of Calcineurin Inhibitors-Related Chronic Kidney Disease in Cardiac Transplantation

The effect of calcineurin inhibitors on endothelial function in renal transplant recipients

Calcineurin-Inhibitor Minimization In Liver Transplant Patients With Calcineurin-Inhibitor-Related Renal Dysfunction: A Meta-Analysis

Treatment with calcimimetics in kidney transplantation

Progress in the Application of Immunosuppressants to Renal Transplant

Calcineurin inhibitors and the renin–angiotensin–aldosterone system

Calcineurin inhibition, cardiovascular consequences, vascular resistance, and potential responses

Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

Prophylaxis of Chronic Kidney Disease after Liver Transplantation - Experience from West China

Development of calciphylaxis in kidney transplant recipients with a functioning graft

Systematic Review of Calcineurin Inhibitors and Incidence of Skin Malignancies after Kidney Transplantation in Adult Patients: A Study of 309,551 Cases

Calciphylaxis after kidney transplantation: a rare but life-threatening disorder

Long-term clinicopathological impact of calcineurin inhibitor cessation without specific cytoreductive induction in kidney transplantation

Chronic Cyclosporine Nephrotoxicity: New Insights and Preventive Strategies

Immunosuppression in Kidney Transplant Recipients: An Update for the General Nephrologist

Calcineurin inhibitors' impact on cardiovascular and renal function, a descriptive study in lung transplant recipients from the North of Spain

Calcineurin Inhibitor - A Necessary Evil: Pharmacogenetical Approach to a Promising Future

Calcineurin inhibitors and nephrotoxicity in children

Bridging the Gap Between CKD Management Paradigms in Transplant and Nontransplant Settings: Published Evidence, Challenges, and Perspectives

Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation

Management of Long-Term complications from immunosuppression